These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34608741)

  • 1. Statistical detection of synergy: New methods and a comparative study.
    Thas O; Tourny A; Verbist B; Hawinkel S; Nazarov M; Mutambanengwe K; Bijnens L
    Pharm Stat; 2022 Mar; 21(2):345-360. PubMed ID: 34608741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.
    Van der Borght K; Tourny A; Bagdziunas R; Thas O; Nazarov M; Turner H; Verbist B; Ceulemans H
    Sci Rep; 2017 Dec; 7(1):17935. PubMed ID: 29263342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.
    Amzallag A; Ramaswamy S; Benes CH
    BMC Bioinformatics; 2019 Feb; 20(1):83. PubMed ID: 30777010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets.
    Zheng S; Wang W; Aldahdooh J; Malyutina A; Shadbahr T; Tanoli Z; Pessia A; Tang J
    Genomics Proteomics Bioinformatics; 2022 Jun; 20(3):587-596. PubMed ID: 35085776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen.
    Perez DR; Edwards BS; Sklar LA; Chigaev A
    SLAS Discov; 2018 Aug; 23(7):751-760. PubMed ID: 29842834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-parametric synergy modeling of chemical compounds with Gaussian processes.
    Shapovalova Y; Heskes T; Dijkstra T
    BMC Bioinformatics; 2022 Jan; 23(1):14. PubMed ID: 34991440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
    Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
    Oncotarget; 2017 Nov; 8(61):103952-103967. PubMed ID: 29262612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations.
    Liu Q; Xie L
    PLoS Comput Biol; 2021 Feb; 17(2):e1008653. PubMed ID: 33577560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Methods for Quantifying Drug Synergism.
    Ma J; Motsinger-Reif A
    Proteom Bioinform; 2019 Jul; 1(2):43-48. PubMed ID: 32043089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy evaluation of non-normalizable dose-response data: Generalization of combination index for the linear effect of drugs.
    Novotný B; Nagy M; Kurin E
    Pharm Stat; 2021 Nov; 20(6):982-989. PubMed ID: 33764621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charting the Fragmented Landscape of Drug Synergy.
    Meyer CT; Wooten DJ; Lopez CF; Quaranta V
    Trends Pharmacol Sci; 2020 Apr; 41(4):266-280. PubMed ID: 32113653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is synergy? The Saariselkä agreement revisited.
    Tang J; Wennerberg K; Aittokallio T
    Front Pharmacol; 2015; 6():181. PubMed ID: 26388771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive Dose Response Models: Defining Synergy.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2019; 10():1384. PubMed ID: 31849651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theory of synergistic effects: Hill-type response surfaces as 'null-interaction' models for mixtures.
    Schindler M
    Theor Biol Med Model; 2017 Aug; 14(1):15. PubMed ID: 28768512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple test for synergy for a small number of combinations.
    Novick SJ
    Stat Med; 2013 Dec; 32(29):5145-55. PubMed ID: 23904140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovering anti-platelet drug combinations with an integrated model of activator-inhibitor relationships, activator-activator synergies and inhibitor-inhibitor synergies.
    Lombardi F; Golla K; Fitzpatrick DJ; Casey FP; Moran N; Shields DC
    PLoS Comput Biol; 2015 Apr; 11(4):e1004119. PubMed ID: 25875950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacodynamic model of clinical synergy in multiple myeloma.
    Sudalagunta P; Silva MC; Canevarolo RR; Alugubelli RR; DeAvila G; Tungesvik A; Perez L; Gatenby R; Gillies R; Baz R; Meads MB; Shain KH; Silva AS
    EBioMedicine; 2020 Apr; 54():102716. PubMed ID: 32268267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2018; 9():31. PubMed ID: 29467650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines.
    Roell KR; Reif DM; Motsinger-Reif AA
    Front Pharmacol; 2017; 8():158. PubMed ID: 28473769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.